AbbVie tapped Disco Pharmaceuticals for further development of bispecific cancer medicine
AbbVie has agreed to pay up to $2.54 billion to develop cancer treatments with Disco Pharmaceuticals, the Germany-based private biotech announced on Thursday, November 19, 2026.
AbbVie is an American biopharmaceutical company specializing in immunology, oncology, neuroscience, aesthetics, eye care, and virology while Dsico Pharmaceuticals, a German, private oncology biotechnology company focuses on targeted cancer therapies.
The news from Disco Pharmaceuticals has marked an early-stage push by the drug maker on next-generation bispecific therapies.
Bispecific antibodies, a class of cancer medicines that bind two targets at once, have drawn increased interest from big drug makers including Bristol Myers Squibb, Pfizer and Merck.
In January, AbbVie paid RemeGen $650 million upfront for rights outside China to a bispecific medicine targeting solid tumors.
Bispecific medicine targeting solid tumors is a lab-engineered cancer therapy designed to bind to two different targets or two different sites on the same target, at the same time, creating a dual binding that lets the drug bring immune cells to tumor cells or block two cancer pathways simultaneously.
Disco will receive $40 million upfront and up to $2.5 billion in milestone payments as part of the deal to develop so-called AND-gated bispecific therapeutics for solid tumors.
It will also be eligible for tiered royalties on worldwide net sales.
The approach is designed to recognize cancer cells only when two target proteins are present simultaneously, potentially reducing damage to healthy tissue.
Disco CEO Mark Manfredi said his company will be responsible for the research and discovery. AbbVie will have the right to exclusively license selected programs for further development.
"(AbbVie) brings a wealth of information, a wealth of experience in target biology, so we will learn from them and we will work with them on how to select targets," said Manfredi of their deal.
The deal is at a very early stage and Disco did not disclose how many programs could be covered or when would they enter clinical development, and AbbVie's license option applies only after Disco completes specified research.
However, Disco has been developing AND-gated therapies for small-cell lung and colorectal cancer, and Manfredi said the company will select a development candidate in the second half of next year.